Author/Authors :
Pezeshki, Shaghayegh Department of Immunology - School of Medicine - Iran University of Medical Sciences, Tehran, Iran , Hashemi, Payam School of Medicine - Tehran University of Medical Science, Tehran, Iran , Salimi, Alireza Department of Molecular and Cellular Sciences - Faculty of Advanced Science and Technology - Tehran Medical Sciences - Islamic Azad University, Tehran, Iran , Ebrahimi, Sheida Department of Genetic - Faculty of biology - Yazd University, Yazd, Iran , Javanzad, Mandana Medical Branch - Islamic Azad University, Tehran, Iran , Monfaredan, Amir Department of Hematology - Faculty of Medicine - Tabriz Branch - Islamic Azad University, Tabriz, Iran
Abstract :
Background: Prostate cancer (PC) is one of the most abundant cancers among men, and In Iran, has been responsible for 6% of all deaths from cancer in men. NUF2 and GMNN genes are considered as loci of susceptibility to tumorigenesis in humans. Alterations in expression of these genes have been reported in various malignancies. The aim of our study was to test whether different NUF2 and GMNN expression
levels are associated with PC incidence and hence, might be considered as new molecular tools for PC
screening.
Methods: Biopsy samples from 40 PC patients and 41 healthy Iranian men were used to determine the
relative gene expression. After RNA extraction and cDNA synthesis, samples were analyzed using TaqMan
Quantitative Real time PCR. Patients’ background information, included smoking habits and family histories
of PC, were recorded. Stages and grades of their PC were classified by the TNM tumor, node, metastasis
(TMN) staging system based on standard guidelines.
Results: NUF2 expression did not significantly differ between the groups, while GMNN expression was
significantly greater in the PC specimens than in the controls.
Conclusions: Regarding the significant role of GMNN in various tumor phenotypes, and its importance in PC progression, the alteration in GMNN expression in PC samples vs. controls indicate that the genetic profiling of this cancer might be considered to personalize therapy for each patient in the future.
Keywords :
Family history , Geminin (GMNN) , Tumor staging , NUF2 , Prostate cancer